Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Share-based Compensation: 2015-2020

Historic Share-based Compensation for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $784,693.

  • Outlook Therapeutics' Share-based Compensation rose 283.58% to $784,693 in Q3 2020 from the same period last year, while for Sep 2020 it was $2.8 million, marking a year-over-year increase of 113.76%. This contributed to the annual value of $5.4 million for FY2024, which is 2.92% down from last year.
  • Per Outlook Therapeutics' latest filing, its Share-based Compensation stood at $784,693 for Q3 2020, which was down 42.25% from $1.4 million recorded in Q2 2020.
  • In the past 5 years, Outlook Therapeutics' Share-based Compensation ranged from a high of $10.6 million in Q2 2016 and a low of -$4.4 million during Q1 2016.
  • Its 3-year average for Share-based Compensation is $383,347, with a median of $267,742 in 2019.
  • In the last 5 years, Outlook Therapeutics' Share-based Compensation tumbled by 113.35% in 2019 and then skyrocketed by 4,445.82% in 2020.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Share-based Compensation stood at $2.5 million in 2016, then decreased by 23.30% to $1.9 million in 2017, then slumped by 53.84% to $872,289 in 2018, then slumped by 58.79% to $359,477 in 2019, then surged by 283.58% to $784,693 in 2020.
  • Its last three reported values are $784,693 in Q3 2020, $1.4 million for Q2 2020, and $304,539 during Q1 2020.